PL3003383T3 - Stała kompozycja do podawania doustnego zawierająca kwas ibandronowy lub jego farmaceutycznie dopuszczalną sól i witaminę d - Google Patents

Stała kompozycja do podawania doustnego zawierająca kwas ibandronowy lub jego farmaceutycznie dopuszczalną sól i witaminę d

Info

Publication number
PL3003383T3
PL3003383T3 PL14730606T PL14730606T PL3003383T3 PL 3003383 T3 PL3003383 T3 PL 3003383T3 PL 14730606 T PL14730606 T PL 14730606T PL 14730606 T PL14730606 T PL 14730606T PL 3003383 T3 PL3003383 T3 PL 3003383T3
Authority
PL
Poland
Prior art keywords
vitamin
pharmaceutically acceptable
acceptable salt
oral administration
solid composition
Prior art date
Application number
PL14730606T
Other languages
English (en)
Inventor
João Pedro SILVA SERRA
Isabel Maria SOARES
Original Assignee
Tecnimede Soc Tecnico Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3003383(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Soc Tecnico Medicinal S A filed Critical Tecnimede Soc Tecnico Medicinal S A
Publication of PL3003383T3 publication Critical patent/PL3003383T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14730606T 2013-05-31 2014-05-30 Stała kompozycja do podawania doustnego zawierająca kwas ibandronowy lub jego farmaceutycznie dopuszczalną sól i witaminę d PL3003383T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
EP14730606.2A EP3003383B1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d
PCT/PT2014/000036 WO2014193255A1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d

Publications (1)

Publication Number Publication Date
PL3003383T3 true PL3003383T3 (pl) 2019-04-30

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14730606T PL3003383T3 (pl) 2013-05-31 2014-05-30 Stała kompozycja do podawania doustnego zawierająca kwas ibandronowy lub jego farmaceutycznie dopuszczalną sól i witaminę d

Country Status (16)

Country Link
US (1) US20160106766A1 (pl)
EP (1) EP3003383B1 (pl)
BR (1) BR112015029897A2 (pl)
CL (1) CL2015003468A1 (pl)
DK (1) DK3003383T3 (pl)
ES (1) ES2705074T3 (pl)
HU (1) HUE040666T2 (pl)
LT (1) LT3003383T (pl)
MA (1) MA38688B1 (pl)
MX (1) MX364680B (pl)
PL (1) PL3003383T3 (pl)
PT (2) PT106978A (pl)
RS (1) RS58133B1 (pl)
SI (1) SI3003383T1 (pl)
TR (1) TR201821157T4 (pl)
WO (1) WO2014193255A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
AU2003226148A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
EP2124963A4 (en) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc COMPOSITION WITH A BISPHOSPHONIC ACID IN COMBINATION WITH VITAMIN D
EP1972341A1 (en) 2007-03-23 2008-09-24 Novartis AG Pharmaceutical compositions comprising a bisphosphonate and vitamin D
EP2201937A1 (en) * 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin D or derivatives thereof
EP2416756A2 (en) * 2009-04-10 2012-02-15 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
GB2502032B (en) * 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition

Also Published As

Publication number Publication date
RS58133B1 (sr) 2019-02-28
MA38688B1 (fr) 2018-08-31
SI3003383T1 (sl) 2019-03-29
EP3003383B1 (en) 2018-10-03
BR112015029897A2 (pt) 2017-07-25
WO2014193255A1 (en) 2014-12-04
LT3003383T (lt) 2019-03-12
PT106978A (pt) 2014-12-02
DK3003383T3 (en) 2019-01-28
MX2015016497A (es) 2016-09-08
MA38688A1 (fr) 2017-07-31
HUE040666T2 (hu) 2019-08-28
EP3003383A1 (en) 2016-04-13
CL2015003468A1 (es) 2016-07-22
ES2705074T3 (es) 2019-03-21
US20160106766A1 (en) 2016-04-21
TR201821157T4 (tr) 2019-02-21
MX364680B (es) 2019-05-03
PT3003383T (pt) 2019-01-16

Similar Documents

Publication Publication Date Title
ZA201509239B (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
HUE040666T2 (hu) Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció
IL246377A0 (en) Pharmaceutical preparations for oral administration
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
ZA201405756B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
LT2815752T (lt) Peroralinė farmacinė kompozicija
ZA201306395B (en) New low side effect pharmaceutical composition containing antituberculosis drugs
LT2983650T (lt) Peroralinė farmacinė kompozicija, apimanti maskuoto skonio n-acetilcisteiną
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
IL241367A0 (en) Pharmaceutical composition for oral dual use of tablets of sulfate salts and methods of using it
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
HUE061697T2 (hu) Stabil gyógyszerkészítmény orális adagolásra
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
IL239958A (en) A chewable oral preparation and process for preparing it
PL2714042T3 (pl) Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
ZA201604100B (en) Gastro-retentive oral pharmaceutical compositions
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3162368A4 (en) Pharmaceutical composition for oral administration
EP3082783A4 (en) Stable oral pharmaceutical composition
PL2988782T3 (pl) Postacie dawkowania do podawania substancji czynnych drogą doustną
SI3079672T1 (sl) Farmacevtski sestavek, ki vsebuje farmacevtsko sprejemljivo sol razagilina
HK1230071A1 (en) Oral pharmaceutical composition
GB201318635D0 (en) Preservative free pharmaceutical compositions for ophthalmic administration